Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | SVP, CHIEF HR OFFICER | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,946 |
Ending reported balance
After 2026-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Sale · Disposed 1,485 · Balance 57,033 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. Row 2 · 2026-03-09 · Sale · Disposed 5,087 · Balance 51,946 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. F2: The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.
F2: The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 10, 2026 20:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,087 | $74.13 | $377,099.31 |
DisclosureSEC source: 0001946439-26-000010 · wk-form4_1773173188.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,946 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. F2 · price: The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,485 | $75.00 | $111,375.00 |
DisclosureSEC source: 0001946439-26-000010 · wk-form4_1773173188.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,033 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:57 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,555 | $73.90 | $114,914.50 |
DisclosureSEC source: 0001946439-26-000008 · wk-form4_1772492277.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,518 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:57 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 10,810 | $77.15 | $833,991.50 |
DisclosureSEC source: 0001946439-26-000008 · wk-form4_1772492277.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,073 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:31 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,730 | $77.99 | $134,922.70 |
DisclosureSEC source: 0001946439-26-000006 · wk-form4_1771885891.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,263 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. F2 · price: The shares were sold in multiple trades at prices ranging from $77.45 to $78.58. The price reported above reflects the weighted average sales price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 22:31 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 2,084 | $77.53 | $161,572.52 |
DisclosureSEC source: 0001946439-26-000006 · wk-form4_1771885891.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,993 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,290 | $77.36 | $99,794.40 |
DisclosureSEC source: 0001946439-26-000004 · wk-form4_1771362300.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,077 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,020 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,180 | $76.70 | $90,506.00 |
DisclosureSEC source: 0001946439-26-000004 · wk-form4_1771362300.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,367 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,264 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:12 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,017 | $76.25 | $230,046.25 |
DisclosureSEC source: 0001946439-26-000002 · wk-form4_1771017161.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,547 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,104 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:47 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,622 | $82.40 | $133,652.80 |
DisclosureSEC source: 0001946439-25-000019 · wk-form4_1766180822.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,564 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 21:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,000 | $98.04 | $98,040.00 |
DisclosureSEC source: 0001946439-25-000017 · wk-form4_1758575697.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 23:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,710 | $97.71 | $167,084.10 |
DisclosureSEC source: 0001946439-25-000015 · wk-form4_1757978243.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,186 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,108 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| August 22, 2025 Filed Aug 25, 2025 20:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,763 | $91.10 | $160,609.30 |
DisclosureSEC source: 0001946439-25-000013 · wk-form4_1756153167.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,896 F1 · price: The shares were sold in multiple trades at prices ranging from $91.01 to $91.19. The price reported above reflects the weighted average sales price. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 20:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,866 | $65.00 | $121,290.00 |
DisclosureSEC source: 0001946439-25-000010 · wk-form4_1742501635.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:28 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,000 | $60.86 | $60,860.00 |
DisclosureSEC source: 0001946439-25-000008 · wk-form4_1741652880.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,099 | $61.89 | $68,017.11 |
DisclosureSEC source: 0001946439-25-000006 · wk-form4_1741125961.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,525 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,039 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 21:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,000 | $60.20 | $60,200.00 |
DisclosureSEC source: 0001946439-25-000004 · wk-form4_1740432806.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,624 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 01:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,196 | $58.92 | $70,468.32 |
DisclosureSEC source: 0001946439-25-000002 · wk-form4_1739927578.xml · nonDerivative · entry 3 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,624 F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,019 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 8,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001946439-25-000002 · wk-form4_1739927578.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,820 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 13,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001946439-25-000002 · wk-form4_1739927578.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,116 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 22:08 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,000 | $60.00 | $60,000.00 |
DisclosureSEC source: 0001946439-24-000008 · wk-form4_1734041311.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,059 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 20:23 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,486 | $56.15 | $83,438.90 |
DisclosureSEC source: 0001946439-24-000006 · wk-form4_1726258989.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,059 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,108 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 21:59 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,173 | $67.67 | $79,376.91 |
DisclosureSEC source: 0001946439-24-000004 · wk-form4_1709330377.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,545 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,039 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:30 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 8,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001946439-24-000002 · wk-form4_1708119020.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,718 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:30 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 12,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001946439-24-000002 · wk-form4_1708119020.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,666 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 23:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 2,622 | $53.81 | $141,089.82 |
DisclosureSEC source: 0001946439-23-000005 · wk-form4_1700176406.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,587 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $53.80 to $53.91, inclusive. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 12:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,486 | $61.91 | $91,998.26 |
DisclosureSEC source: 0001946439-23-000003 · wk-form4_1694692910.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,209 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,108 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 8,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041721 · tm2311710-3_4seq1.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,695 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 12,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041721 · tm2311710-3_4seq1.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,591 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 23:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 16,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009623 · form4-09142022_040950.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,433 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of September 12, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.